

Corporate Presentation

August 2022

Disclaimer

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding Bolt Biotherapeutics, Inc. (the "Company," "we," "us," or "our")'s future financial condition, ability to achieve upcoming milestones for our product candidates, the timing of our clinical trials and the success and results of our pipeline programs, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially" "predict," "should," "will" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the success, cost and timing of our product development activities and clinical trials; our expectations about the timing of achieving regulatory approval and the cost of our development programs; our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; our ability to fund our clinical programs and the sufficiency of our cash, cash equivalents, and marketable securities to fund operations through 2025 and the achievement of key milestones; the commercialization of our product candidates, if approved; our plans to research, develop and commercialize our product candidates; our ability to attract collaborators with development, regulatory and commercialization expertise; future agreements with third parties in connection with the commercialization of our product candidates; the success of our current collaborations with third parties, including our collaborations with Bristol-Myers Squibb Company, Innovent Biologics, Inc., Genmab A/S and Toray Industries, Inc.; the achievement of milestone payments or any tiered royalties related to our collaborations; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; the rate and degree of market acceptance of our product candidates; and regulatory developments in the United States and foreign countries. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2021. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.



Bolt Biotherapeutics Today

Experts in Myeloid Biology and Cancer Drug Development

- Prioritizing advancement of two promising programs
 - BDC-1001, a HER2-targeting Boltbody[™] ISAC
 - BDC-3042, a Dectin-2 agonist antibody
- Focusing on next-generation ISAC programs, including our collaborations
 - Discontinued BDC-2034; potential to pursue new CEA ISAC program in the future
 - Pursuing multiple ISACs with collaborators that cover development costs through initial proof-ofconcept
- Expected cash runway extended by two years through 2025



Building Value in 2022 and Beyond

• Strong progress in 2022

- BDC-1001: Steady enrollment in dose-escalation studies
- BDC-3042: IND-enabling activities on track
- Current cash of \$224M¹ funds operations through multiple clinical milestones, including:
 - BDC-1001 (HER2 Boltbody™ ISAC)
 - Complete monotherapy dose escalation, determine RP2D in 2H 2022
 - Complete Opdivo[®] combination dose escalation, determine RP2D in 2H 2022

BDC-3042 (Dectin-2 Agonist Antibody)

- Submit IND in 1H 2023
- First-in-human Phase 1 clinical trial planned for 2023 start



Prioritized Pipeline Near-term Milestones and Partner-funded Programs

Proprietary Development Programs						
BDC-1001 (HER2)	HER2-expressing solid tumors	 Multi-arm Phase 1/2 Trial monotherapy & Opdivo[®] combination Next milestone: RP2D in 2H22 				
BDC-3042 (Dectin-2)	Range of solid tumors with high unmet need	 IND-enabling studies underway IND and Phase 1 in 2023 				
Next-Gen ISAC (Undisclosed)	Solid tumors	• Discovery				
Next-generation Boltbody™ ISAC Collaborations						
Genmab	Innovative leader in antibody and bispecific development in oncology	 Funds 3 bispecific Boltbody™ ISACs through early clinical development Option for Bolt to co-develop & commercialize 1 candidate in certain regions 				
Innovent	Fully integrated biopharma with large antibody library and strong presence in Greater China	 Funds up to 3 Boltbody™ ISACs through early clinical development Option for Bolt to co-develop & commercialize 2 candidates in certain regions 				
'TORAY'	Global leader in innovative technologies, conducting cancer immunotherapeutics research	 Toray funds Boltbody[™] ISAC for a specific, novel target through Phase 1 Global co-development & co-commercialization rights to Bolt 				




5



BDC-1001: HER2 Boltbody[™] ISAC

BDC-1001 Boltbody[™] ISAC Program in Phase 1/2 Development

Targeting HER2-Expressing Solid Tumors



BDC-1001

 Trastuzumab biosimilar (anti-HER2) conjugated via a non-cleavable linker to a proprietary TLR7/8 agonist

Bristol Myers Squibb Partnership

- Investigating BDC-1001 in combination with PD-1 checkpoint inhibitor Opdivo[®] (nivolumab)
- Clinical collaboration, Opdivo supplied at no cost

Dose-escalation portion of Phase 1/2 clinical program ongoing


- Interim monotherapy data reported at ESMO Immuno-Oncology Congress 2021 for subjects enrolled in initial cohorts of study
- Enrolled q2w monotherapy & combination with Opdivo, follow-up ongoing
- Weekly dosing underway in monotherapy & Opdivo combination dose escalation
- RP2D expected in 2H 2022



Investigating BDC-1001 Monotherapy & Combination with Opdivo®

Increasing Drug Exposure via Weekly Administration

Safety, PK, PD Biomarkers, Efficacy





BDC-1001 Showing Promise in Phase 1/2 Trial Completion of Dose-escalation Expected in 2022


Favorable	 Demonstrated favorable safety & tolerability to date 	
Safety Profile	 Dose-escalation monotherapy and combination studies with Opdivo[®] are ongoing 	

 Tumor microenvironment & plasma biomarker changes consistent with MOA No evidence of anti-drug antibody (ADA) formation
 Early signs of disease control, even below target exposure level
 Disease control (SD or PR) noted in 13/40 evaluable subjects in multiple tumor types
 Durability: 6 patients with stable disease >12 weeks; PR maintained >52 weeks

Dose-Escalation
 Human PK model predicts achieving threshold exposure with more frequent dosing
 Weekly dosing underway



BDC-1001 PK Parameters in Ongoing Dose-escalation Trial Show Increase with Ascending Dose Treatment



Summary of PK Data


- Target C_{min} levels not yet achieved
 - (C_{min} of ~16 µg/ml for optimal efficacy in preclinical models)^{1,3}
- Clinical PK modeling suggests higher sustained trough levels >16 µg/mL can be achieved in humans via higher q2w or weekly dosing
- Observed exposure levels to date are lower than predicted based on NHP (non-human primate) modeling data; BDC-1001 does not follow-presumed allometric scaling regarding clearance
- C_{max} increases proportionally with dose



Sharma MR, et al., ESMO I-O Poster (2021); data as of October 6, 2021

1. Ackerman SE, et al. *Nature Cancer*. 2021;2:18–33.
 3. Bolt Biotherapeutics internal data.

BDC-1001 Surrogate Shows Dose-dependent Efficacy & Pharmacodynamic Responses HCC1954 IHC3+ Xenograft Model (Functional Myeloid Cells Only)



Efficacy

• Preclinical experiments indicate a minimal target serum concentration of ~16 μg/ml at trough for optimal efficacy


Pharmacodynamic Biomarkers

- Increases in proinflammatory cytokines & chemokines in tumor; modest increases in serum
- Recruitment of dendritic cells & macrophages to tumor

SCID/Beige mice were dosed with BDC-1001 surrogate every 5 days through day 25 with cytokines and myeloid infiltration measured 24 hours or 9 days following the first dose, respectively. Representative figures are from independent experiments.



Evidence of Activated Tumor Immunity in Paired Tissue Biopsies Clinical Trial Subject with Cervical Cancer on BDC-1001 5 mg/kg q3w



*Dark blue staining in these panels is cell nuclei

Sharma MR, et al., ESMO I-O Poster (2021); data as of October 6, 2021

12

BDC-1001 Clinical Activity Seen in 13/40 Tumor-evaluable Subjects* Across Multiple Solid Tumor Types & Dose Levels (2-20 mg/kg)

Tumor Response	Site of Primary Tumor	Duration of Disease Control (PR or SD) in Weeks	Cohort	
Partial response (>36 weeks)	Colorectal	36 [§]	5 mg/kg q3w	
	Endometrial	24	2 mg/kg q3w	
	Cervix	23+	5 mg/kg q3w	
Long-term stable disease	Breast	15+	8 mg/kg q3w	
(>12 weeks)	Melanoma	13+	8 mg/kg q3w	
	Colorectal	19+	8 mg/kg q2w	
	Colorectal	13+	8 mg/kg q2w	
	Gastro-esophageal	10+	12 mg/kg q3w	
	Ovarian	6	20 mg/kg q3w	
Stable disease	Colorectal	6	2 mg/kg q3w	
at Week 6 scan	Colorectal	6	5 mg/kg q3w	
	Bile duct	6	8 mg/kg q3w	
	Gastro-esophageal	7+	8 mg/kg q3w	

*Defined as subjects with baseline & at least one post baseline tumor scan available

[§]Patient continued with PR at 52 weeks without any subsequent therapies

+ Denotes subjects are still on treatment



PK Modeling Predicts Higher Exposure with More Frequent Dosing

	Median AUCs over 3 weeks (µg*day/mL)⁴	CL (mL/day/kg) ^{5,6}	Median C _{max} ,ss (μg/mL) ⁴	Median C _{min} ,ss (μg/mL) ⁴	Median half-life (days) ^{5,6}
Trastuzumab (8 then 6 mg/kg q3w)	1600	3.8	178	29	25-30
BDC-1001 @ 20 mg/kg q3w	828	25	335	1.4	3
BDC-1001 @ 20 mg/kg q2w	1242	25	362	7.0	3
BDC-1001 @ 8 mg/kg q1w	1010	25	151	14.6	3
BDC-1001 @ 12 mg/kg q1w	1510	25	227	21.9	3
BDC-1001 @ 20 mg/kg q1w	2520	25	379	36.6	3

SS, steady state

14

Sharma MR, et al., ESMO I-O Poster (2021); data as of October 6, 2021


4. Herceptin Hylecta. Prescribing information. Genentech, Inc. Accessed November 15, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106s000lbl.pdf

5. Quartino AL, et al. *Cancer Chemother Pharmacol*. 2019;88:329-340.

6. Bruno R, et al. Cancer Chemother Pharamcol. 2005;56:361-9.



Continued Opportunity for BDC-1001 in the Dynamic HER2 Therapeutic Market



US + Top5 EU incidence numbers based upon 2022 SEER/American Cancer Society (US) & 2020 European Cancer Information System. HER2 segmentation based upon various scientific publications with HER2-low being IHC2+ unamplified & IHC1+ unamplified.


15



BDC-3042: Dectin-2 Agonist Antibody

BDC-3042 Reprograms Tumor-associated Macrophages via Dectin-2 Agonism

Complementary Approach to ISACs and TLR Agonism to Modulate TME



BDC-3042: Dectin-2 agonist antibody

- Dectin-2 is expressed by tumor-associated macrophages (TAMs) in a wide range of solid tumors
- BDC-3042 activates human TAMs to elicit anti-tumor immune responses

Preclinical Proof of Concept achieved


- Potent activator of human macrophages
 - Activates TAMs within human tumor samples
 - Elicits secretion of pro-inflammatory cytokines & chemokines
 (e.g., TNFα, IL-6, IL-1β, & CCL3)
- Mediates anti-tumor efficacy in humanized mouse model

Status

- IND-enabling activities underway
- Phase 1 initiation planned in 2023




BDC-3042-Mediated Dectin-2 Agonism Activates TAMs & Elicits Anti-tumor Immune Response





Dectin-2 is Preferentially Expressed in Macrophages & BDC-3042 Activates TAMs Within Primary Tumor Samples


Kenkel JA, et al., SITC Poster (2021)





BDC-3042 Mediates Anti-tumor Activity in Humanized Mice Bearing Triple-negative Breast Tumors (MDA-MB-231)

Kenkel JA, et al., AACR Poster (2022)



Each data point represents a unique HSC donor cohort





BDC-2034 CEA Boltbody™ ISAC Program Update


BDC-2034 Update

- BDC-2034 discontinued due to off-target toxicities related to lack of specificity of the targeting antibody
 - Data suggest toxicity resulted from cross-reactivity of BDC-2034 target mAb for CEACAMs other than CEACAM5
 - Significant safety risk in order to achieve serum concentration estimated for human clinical efficacy
- Highly specific CEACAM5 ISAC conjugated to same linker-payload lacked toxicity
 - Highly specific CEACAM5 ISAC (CEA2 ISAC) retains in vivo efficacy and has improved safety margins
 - BDC-2034 linker-payload was well tolerated in non-GLP tox studies when conjugated to other mAbs
- CEACAM5 remains a target of interest to Bolt



Same BDC-2034 Linker-Payload Does Not Cause Toxicity with Other Antibodies

CEACAM5-Specific Antibody Provides Safety Window



Preclinical data shown are the mean and SEM of the peak level following the 1st dose, n=3 per group. All ISACs contained the same linker-payload and were dosed IV at Days 1 and 15. Serum cytokines measured by MSD.





Summary

Building Value in 2022 and Beyond

• Strong progress in 2022

- BDC-1001: Steady enrollment in dose-escalation studies
- BDC-3042: IND-enabling activities on track
- Current cash of \$224M¹ funds operations through multiple clinical milestones, including:
 - BDC-1001 (HER2 Boltbody™ ISAC)
 - Complete monotherapy dose escalation, determine RP2D in 2H 2022
 - Complete Opdivo[®] combination dose escalation, determine RP2D in 2H 2022

BDC-3042 (Dectin-2 Agonist Antibody)

• Submit IND in 2023

25

• First-in-human Phase 1 clinical trial planned for 2023 start





Thank You